share_log

Stephens & Co. Initiates Coverage On Inovio Pharmaceuticals With Overweight Rating, Announces Price Target of $20

Stephens & Co. Initiates Coverage On Inovio Pharmaceuticals With Overweight Rating, Announces Price Target of $20

Stephens & Co.以增持評級啓動對Inovio Pharmicals的報道,宣佈目標股價爲20美元
Benzinga ·  05/14 18:01

Stephens & Co. analyst Sudan Loganathan initiates coverage on Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight rating and announces Price Target of $20.

斯蒂芬斯公司分析師蘇丹·洛加納森以增持評級啓動了對Inovio Pharmicals(納斯達克股票代碼:INO)的報道,並宣佈目標股價爲20美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論